First Patient Dosed in Trial of INT230-6 For Triple-Negative Breast Cancer
Nov 4, 2024 · The first patient has been dosed in a phase 2 clinical trial studying a potential new treatment for localized triple-negative breast cancer (TNBC). Intensity Therapeutics, a biotechnology company, and the Swiss Group for Clinical Cancer Research SAKK, an academic research institute, have announced the start of patient dosing in the INVINCIBLE-4 ...
New study finds triple-negative breast cancer tumors with an …
Apr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not …
Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative …
6 days ago · HealthDay News — For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published online Oct. 23 in The BMJ.. Min He, from Fudan University Shanghai Cancer and Key Laboratory of Breast Cancer, and colleagues conducted a randomized phase 3 trial in seven cancer centers …
Antibody-based treatment for the most aggressive type of breast cancer ...
Nov 4, 2024 · "Dr. Steven Rosen, an executive vice president at City of Hope, proposed that we examine samples from patients with the most aggressive type of breast tumors—triple-negative breast cancer. One ...
Fighting triple-negative breast cancer is hard, but not impossible
Oct 25, 2024 · Most recently, breast cancer doctors say they may have found a new way to fight triple-negative breast cancer– one of the most devasting subtypes of cancer. NBC 5 health reporter Bianca Castro ...
Understanding triple-negative breast cancer and its treatment
Jan 3, 2024 · Triple-negative breast cancer, also called basal-like breast cancer, is a subtype that isn't affected by hormones or the HER2 gene. It grows rapidly, is more likely to spread beyond the breast before diagnosis and is more likely to recur than other breast cancers.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Jul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed...
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer ...
WASHINGTON (July 17, 2023) — How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center who worked in collaboration with scientists at the University of ...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
August 9, 2022, by Edward Winstead. Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative ...
Apr 29, 2020 · The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments.